Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Authors:
- Claire GalloisCGClaire Gallois
- Matteo LandiMLMatteo Landi
- Julien TaiebJTJulien Taieb
- Marine SroussiMSMarine Sroussi
- Bahar Saberzadeh-ArdestaniBSBahar Saberzadeh-Ardestani
- Antoine CazellesACAntoine Cazelles
- Sara LonardiSLSara Lonardi
- Francesca BergamoFBFrancesca Bergamo
- Rossana IntiniRIRossana Intini
- Giulia MaddalenaGMGiulia Maddalena
- Filippo PietrantonioFPFilippo Pietrantonio
- Francesca CortiFCFrancesca Corti
Open Access
- 13 July 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18) , 3771-3778
Abstract
Purpose: Microsatellite instability (MSI) is currently the only predictive biomarker of efficacy of immune checkpoint inhibitors (ICI) in metastatic colorectal cancers (mCRC). However, 10% to 40% of patients with MSI mCRC will experience a primary resistance to ICI. Experimental Design: In two cohorts of patients with MSI mCRC treated with ICI (exploratory, N = 103; validation, N = 35), 3′ RNA sequencing was performed from primary tumors. Previously described single-cell transcriptomic signatures of tumor microenvironment (TME) were analyzed. Results: In the exploratory cohort, the unsupervised clustering allowed the identification of three clusters of tumors with distinct transcriptional profiles: cluster A (“stromalHIGH-proliferationLOW”), cluster B (“stromalHIGH-proliferationMED”), and cluster C (“stromalLOW-proliferationHIGH”), with an enrichment of patients progressing at first disease assessment under ICI in cluster A (30% vs. 12% in cluster B and 8.1% in cluster C; P = 0.074). Progression-free survival (PFS) was also significantly shorter in patients belonging to cluster A, compared with clusters B or C (P < 0.001) with 2-year PFS rates of 33.5%, 80.5%, and 78.3%, respectively. In multivariate analysis, PFS was still significantly longer in patients belonging to cluster B [HR, 0.19; 95% confidence interval (CI), 0.08–0.45; P < 0.001] and cluster C (HR, 0.25; 95% CI, 0.10–0.59; P = 0.02), compared with patients belonging to cluster A. The association of this clustering with PFS under ICI was confirmed in the validation cohort. PFS related to non–ICI-based regimens was not significantly different according to cluster. Conclusions: This unsupervised transcriptomic classification identified three groups of MSI mCRCs with different compositions of TME cells and proliferative capacities of TME/tumor cells. The “stromalHIGH-proliferationLOW” cluster is associated with a poorer prognosis with ICI treatment.Keywords
All Related Versions
Funding Information
- Institut National Du Cancer (NA)
- Institut National de la Santé et de la Recherche Médicale (NA)
- Labex Immuno-Oncology (NA)
This publication has 29 references indexed in Scilit:
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerJournal of Clinical Oncology, 2018
- Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patientsTherapeutic Advances in Medical Oncology, 2018
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- An immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunology, Immunotherapy, 2011